Evidence map›Paper›PMID 38238098›Full record

ArticleAJNR. American journal of neuroradiology2024

Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction.

Nicholas S Cho, Francesco Sanvito, Viên Lam Le, Sonoko Oshima, Ashley Teraishi, Jingwen Yao, Donatello Telesca, Catalina Raymond, Whitney B Pope, Phioanh L Nghiemphu and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AJNR. American journal of neuroradiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Nicholas S ChoFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-8686-0575
Francesco SanvitoFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-3379-9958
Viên Lam LeFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California.
Sonoko OshimaFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California.
Ashley TeraishiFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California.ORCID 0009-0004-3442-8109
Jingwen YaoFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-8828-1841
Donatello TelescaDepartment of Biostatistics (D.T.), Fielding School of Public Health, University of California Los Angeles, Los Angeles, California.
Catalina RaymondFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-2757-439X
Whitney B PopeDepartment of Radiological Sciences (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., W.B.P., N.S., B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-4803-1992
Phioanh L NghiemphuUCLA Neuro-Oncology Program (P.L.N., A.L., T.F.C.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-4064-6079
Albert LaiUCLA Neuro-Oncology Program (P.L.N., A.L., T.F.C.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-7265-2986
Timothy F CloughesyUCLA Neuro-Oncology Program (P.L.N., A.L., T.F.C.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-8656-7483
Noriko SalamonDepartment of Radiological Sciences (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., W.B.P., N.S., B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-3520-9467
Benjamin M EllingsonFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California bellingson@mednet.ucla.edu.ORCID 0000-0002-2764-6640
University of California, Los Angeles · US

Funding

UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GANG LI · 2017 to 2026
$25.2M
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastomaR01CA270027 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TIMOTHY CLOUGHESY, Benjamin M. Ellingson · 2022 to 2026
$3.0M
Quantitative molecular MR-PET imaging of glycolysis in glioblastomaR01CA279984 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Benjamin M. Ellingson, David A. Nathanson · 2023 to 2026
$2.4M
Molecular MR-PET to characterize malignant transformation and identify therapeutic vulnerabilities in human IDH-mutant gliomasF30CA284809 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHO, NICHOLAS S. · 2023 to 2025
$136k
NCI NIH HHS F30 CA284809NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA270027NCI NIH HHS R01 CA279984NIGMS NIH HHS T32 GM008042
6 · The paper itself

Abstract

background and purposeThe T2-FLAIR mismatch sign on MR imaging is a highly specific imaging biomarker of isocitrate dehydrogenase ( MATERIALS AND

methodsTwo cohorts of treatment-naïve, nonenhancing gliomas with known

resultsThresholds of ≥42% T2-FLAIR mismatch volume classified

conclusionsT2-FLAIR digital subtraction maps may be a useful, automated tool to obtain objective segmentations of tumor subregions based on quantitative thresholds for classifying

Indexed as

AstrocytomaBrain NeoplasmsGliomaHumansIsocitrate DehydrogenaseMagnetic Resonance ImagingMutationRetrospective StudiesIsocitrate Dehydrogenase

Identifiers

PMID38238098
PMCPMC11285991
OpenAlexW4390967665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.